Peregrine Capital Management LLC Buys 25,814 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Peregrine Capital Management LLC grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 64.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 66,140 shares of the company's stock after purchasing an additional 25,814 shares during the quarter. Peregrine Capital Management LLC owned about 0.20% of TransMedics Group worth $4,124,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMDX. Hager Investment Management Services LLC bought a new position in TransMedics Group during the fourth quarter worth about $33,000. Sachetta LLC bought a new position in TransMedics Group during the fourth quarter worth about $40,000. Quarry LP boosted its position in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company's stock worth $58,000 after purchasing an additional 312 shares during the period. National Bank of Canada FI boosted its position in shares of TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company's stock valued at $65,000 after acquiring an additional 262 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in shares of TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock valued at $76,000 after acquiring an additional 316 shares during the period. Institutional investors own 99.67% of the company's stock.

TransMedics Group Price Performance

Shares of TMDX stock traded down $3.50 during trading hours on Friday, hitting $71.95. 1,192,967 shares of the company's stock were exchanged, compared to its average volume of 1,278,453. The company has a market capitalization of $2.41 billion, a PE ratio of 76.54 and a beta of 2.12. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The business's 50 day simple moving average is $66.47 and its 200-day simple moving average is $105.05. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares of the company's stock, valued at $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 7.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Robert W. Baird cut their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating for the company in a research report on Wednesday, December 11th. Canaccord Genuity Group cut their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a "buy" rating for the company in a research report on Wednesday, November 20th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Finally, Piper Sandler cut their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating for the company in a research report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.